Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR-T for Refractory B-Cell Non-Hodgkin Lymphoma
NCT02134262Phase 2Unknown
- Sponsor
- Jichi Medical University
- Start
- May 2014
- Primary completion
- Mar 2017
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of anti-CD19 CAR-T cells in B-cell non-Hodgkin lymphoma, sponsored by Jichi Medical University. Primary endpoints: Toxicity Profile at 12 weeks and Quality test of CD19-CAR-T. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02134262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134262.